Insider · CIK 0001718004
Yezan Munther Haddadin
Files at OTLK (Outlook Therapeutics, Inc.). First filing May 27, 2026, latest Jun 3, 2026.
In brief
Yezan Munther Haddadin files SEC Form 4 as director at OTLK (Outlook Therapeutics, Inc.). Since May 27, 2026, Yezan Munther Haddadin has reported 2 open-market buys worth $39k and 0 open-market sells worth $0, the latest filed on Jun 3, 2026.
A track record needs three past buys with six months of prices behind them; Yezan Munther Haddadin has 0, so none is measured yet.
The newest scored trade: bought $24k of OTLK on Jun 2, 2026, filed Jun 3, 2026, scored 45 (moderate). In the last 12 months: 2 buys worth $39k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
OTLK: Outlook Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Outlook Therapeutics, Inc. | $24k 29,000 shares | +78% | - | |
| 40Moderate | Outlook Therapeutics, Inc. | $15k 34,000 shares | +1074% | - |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stock | +29,000 | $0.83 | $24k | 66,167 | Jun 3, 2026 |
| May 26, 2026 | OTLK Outlook Therapeutics, Inc. | POpen-market purchase Common Stock | +34,000 | $0.44 | $15k | 37,167 | May 27, 2026 |
| Oct 1, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +286,734 | $0.00 | $0 | 286,734 | Oct 3, 2025 |
| Oct 3, 2025 | OTLK Outlook Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +95,969 | $0.00 | $0 | 95,969 | Oct 3, 2025 |
Questions about Yezan Munther Haddadin
Answered from the filings on this page, as of the latest one.
Is Yezan Munther Haddadin buying or selling?
In the last 12 months Yezan Munther Haddadin reported 2 open-market buys worth $39k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $24k of OTLK on Jun 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Yezan Munther Haddadin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yezan Munther Haddadin has 0.
Where does Yezan Munther Haddadin file Form 4?
Yezan Munther Haddadin has filed Form 4 at OTLK (Outlook Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.